IGFBP1 Is a Predictive Factor for Haematogenous Metastasis in Patients With Gastric Cancer

Anticancer Res. 2019 Jun;39(6):2829-2837. doi: 10.21873/anticanres.13411.

Abstract

Background/aim: The clinicopathological significance and prognostic value of insulin-like growth factor binding protein 1 (IGFBP1) in gastric cancer have not been investigated to date. This study aimed to investigate the relationship of IGFBP1 expression with clinicopathological variables and prognosis.

Materials and methods: The correlation of IGFBP1 expression with the clinicopathological factors and the correlation of clinicopathogical factors with haematogenous metastasis in 219 gastric cancer patients who underwent surgery was examined.

Results: High IGFBP1 expression was significantly associated with a poorer disease-specific survival (p<0.001) and relapse-free survival (p<0.001) in univariable analysis although IGFBP1 was not an independent prognostic factor. High IGFBP1 expression was the only independent risk factor of haematogenous metastasis.

Conclusion: High IGFBP1 expression was associated with haematogenous metastasis and poor survival. IGFBP1 might become a new prognostic factor and a target of molecular targeted therapy of gastric cancer.

Keywords: Gastric cancer; IGFBP1; angiogenesis; hematogenous metastasis; immunohistochemistry; tumour progression.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Gastrectomy / methods*
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Insulin-Like Growth Factor Binding Protein 1 / metabolism*
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Prognosis
  • Stomach Neoplasms / metabolism
  • Stomach Neoplasms / pathology*
  • Stomach Neoplasms / surgery*
  • Survival Analysis
  • Up-Regulation*
  • Young Adult

Substances

  • IGFBP1 protein, human
  • Insulin-Like Growth Factor Binding Protein 1